GlassScriptPhysician profile
Matthew Clark
NPI 1053433250
$6,724.81
in general payments reported to CMS, 2019-2025
24 companies · $1,348 in 2025
The $1,348 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $466 · 2021: $788 · 2022: $1,157 · 2023: $1,172 · 2024: $1,442 · 2025: $1,348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,862 · Education: $99.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,861.91 |
| Education | $99.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,631.09 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $1,194.95 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,091.58 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $499.21 | 2019-2025 | Dupixent |
| Amgen INC. | $422.13 | 2021-2025 | Tezspire |
| Optinose US, INC. | $403.17 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $283.54 | 2022-2025 | |
| Kaleo, INC. | $254.03 | 2019-2023 | Auvi-Q |
| Grifols USA, LLC | $167.08 | 2021-2025 | Xembify, Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $147.47 | 2021-2025 | Cuvitru, Takhzyro |
| Pfizer INC. | $123.82 | 2020-2024 | |
| Ars Pharmaceuticals Operations, INC. | $83.49 | 2025 | Neffy |
| Aimmune Therapeutics, INC. | $74.51 | 2020-2022 | |
| Mylan Specialty L.P. | $65.30 | 2019-2024 | Yupelri |
| Pharming Healthcare, INC. | $54.69 | 2023-2024 | Ruconest |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $42.68 | 2025 | Alvesco |
| Hikma Pharmaceuticals USA | $32.31 | 2022-2024 | Ryaltris |
| Biocryst US Sales Co., LLC | $31.11 | 2024 | Orladeyo |
| Teva Pharmaceuticals USA, INC. | $25.76 | 2022 | |
| Ionis Pharmaceuticals, INC. | $25.26 | 2025 | Dawnzera |
| Leo Pharma INC. | $20.38 | 2024 | Adbry |
| Inspire Medical Systems, INC. | $20.17 | 2023 | Inspire |
| Csl Behring | $18.76 | 2025 | Andembry |
| Merck Sharp & Dohme LLC | $12.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.